ValtedSeq Revenue and Competitors

Location

$12.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ValtedSeq's estimated annual revenue is currently $465k per year.(i)
  • ValtedSeq's estimated revenue per employee is $77,500
  • ValtedSeq's total funding is $12.5M.

Employee Data

  • ValtedSeq has 6 Employees.(i)
  • ValtedSeq grew their employee count by -50% last year.

ValtedSeq's People

NameTitleEmail/Phone
1
Director, HiF-Seq™ platformReveal Email/Phone
2
Senior ScientistReveal Email/Phone
3
Senior Machine Learning and Bioinformatics ScientistReveal Email/Phone
4
Data Scientist- Machine LearningReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M2-60%N/AN/A
#2
$2.9M38-31%$17.5MN/A
#3
$2.9M38-33%$10.5MN/A
#4
$19.8M1280%$69.4MN/A
#5
$9.6M62-15%N/AN/A
#6
$1.4M90%N/AN/A
#7
$2.5M160%N/AN/A
#8
$7.4M480%N/AN/A
#9
$0.2M1-83%N/AN/A
#10
$1.7M1122%N/AN/A
Add Company

What Is ValtedSeq?

Valted Seq is a discovery stage biopharmaceutical company spearheaded by world-renowned scientists Dr. Ted Dawson and Dr. Valina Dawson of Johns Hopkins University. The company was founded on the belief that a deeper understanding of neurodegenerative pathways is essential to develop precision therapeutics and identify novel biomarkers for some of the most challenging neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Valted Seq is part of the D&D Pharmatech/Neuraly family of companies, which works hand in hand with leading medical research institutions to advance groundbreaking healthcare innovations. ValtedSeq is focused on the advancement of NextGen sequencing at the single cell level, as well as developing assays for diagnostic biomarkers,

keywords:N/A

$12.5M

Total Funding

6

Number of Employees

$465k

Revenue (est)

-50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.4M6N/AN/A
#2
$0.4M6-14%N/A
#3
$0.4M60%N/A
#4
$0.4M6-33%N/A
#5
$0.4M60%N/A